{"id":"https://openalex.org/W2017341355","doi":"https://doi.org/10.1016/s0924-977x(03)91795-0","title":"P.1.085 The effect of bupropion on the activity of dopamine transporter in depression \u2014 preliminary results","display_name":"P.1.085 The effect of bupropion on the activity of dopamine transporter in depression \u2014 preliminary results","publication_year":2003,"publication_date":"2003-10-01","ids":{"openalex":"https://openalex.org/W2017341355","doi":"https://doi.org/10.1016/s0924-977x(03)91795-0","mag":"2017341355"},"language":"en","primary_location":{"id":"doi:10.1016/s0924-977x(03)91795-0","doi":"https://doi.org/10.1016/s0924-977x(03)91795-0","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0924-977x(03)91795-0","pdf_url":null,"source":{"id":"https://openalex.org/S168041952","display_name":"European Neuropsychopharmacology","issn_l":"0924-977X","issn":["0924-977X","1873-7862"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Neuropsychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041846479","display_name":"Z Szab\u00f2","orcid":"https://orcid.org/0009-0003-8524-4994","observed_orcids":["https://orcid.org/0009-0003-8524-4994"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Z. Szabo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038719354","display_name":"Mikl\u00f3s \u00c1rgyel\u00e1n","orcid":"https://orcid.org/0000-0002-7254-1776","observed_orcids":["https://orcid.org/0000-0002-7254-1776"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Argyelan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001813391","display_name":"Bal\u00e1zs Kany\u00f3","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Kanyo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053347678","display_name":"A. Juh\u00e1sz","orcid":"https://orcid.org/0000-0003-2704-388X","observed_orcids":["https://orcid.org/0000-0003-2704-388X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Juhasz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014443560","display_name":"Zsuzsa Kov\u00e1cs","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Z.S. Kovacs","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109926636","display_name":"L\u00e1szl\u00f3 P\u00e1vics","orcid":"https://orcid.org/0000-0002-7319-1667","observed_orcids":["https://orcid.org/0000-0002-7319-1667"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Pavics","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5113611827","display_name":"Z. Janka","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Z. Janka","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":null,"fwci":0.4673,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.53078191,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"13","issue":null,"first_page":"S210","last_page":"S210"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.6147000193595886,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.6147000193595886,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.24289999902248383,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.1281999945640564,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cariprazine","display_name":"cariprazine","score":0.9440000057220459},{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":0.9980000257492065},{"id":"https://openalex.org/keywords/negative-symptoms-of-schizophrenia","display_name":"negative symptoms of schizophrenia","score":0.7570000290870667},{"id":"https://openalex.org/keywords/phencyclidine","display_name":"phencyclidine","score":0.722000002861023},{"id":"https://openalex.org/keywords/social-isolation","display_name":"social isolation","score":0.9300000071525574},{"id":"https://openalex.org/keywords/novel-object-recognition","display_name":"novel object recognition","score":0.875},{"id":"https://openalex.org/keywords/locomotor-hyperactivity","display_name":"locomotor hyperactivity","score":0.8450000286102295},{"id":"https://openalex.org/keywords/ultrasonic-vocalizations","display_name":"ultrasonic vocalizations","score":0.9490000009536743},{"id":"https://openalex.org/keywords/fear-memory","display_name":"fear memory","score":0.6200000047683716},{"id":"https://openalex.org/keywords/social-interaction-deficits","display_name":"social interaction deficits","score":0.796999990940094},{"id":"https://openalex.org/keywords/dopamine-transporter","display_name":"dopamine transporter","score":0.6539999842643738},{"id":"https://openalex.org/keywords/bupropion","display_name":"bupropion","score":0.8230000138282776},{"id":"https://openalex.org/keywords/depression","display_name":"depression","score":0.9079999923706055}],"concepts":[{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.9457032084465027},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.6264303922653198},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.6132912635803223},{"id":"https://openalex.org/C199596767","wikidata":"https://www.wikidata.org/wiki/Q21110872","display_name":"Dopamine receptor D3","level":4,"score":0.5834121704101562},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.5627667307853699},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.5369771122932434},{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.511938214302063},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.49866533279418945},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4853467047214508},{"id":"https://openalex.org/C141421786","wikidata":"https://www.wikidata.org/wiki/Q1128897","display_name":"Prepulse inhibition","level":3,"score":0.45466771721839905},{"id":"https://openalex.org/C2778781522","wikidata":"https://www.wikidata.org/wiki/Q417240","display_name":"Atomoxetine","level":4,"score":0.4530661702156067},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.4528222978115082},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.413492888212204},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.37515348196029663},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.333102285861969},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.3122446537017822},{"id":"https://openalex.org/C2780783007","wikidata":"https://www.wikidata.org/wiki/Q181923","display_name":"Attention deficit hyperactivity disorder","level":2,"score":0.2949490249156952},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.2746533751487732},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2718202769756317},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.2661605477333069},{"id":"https://openalex.org/C2777112843","wikidata":"https://www.wikidata.org/wiki/Q422112","display_name":"Methylphenidate","level":3,"score":0.17528575658798218},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.17142745852470398}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s0924-977x(03)91795-0","doi":"https://doi.org/10.1016/s0924-977x(03)91795-0","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0924-977x(03)91795-0","pdf_url":null,"source":{"id":"https://openalex.org/S168041952","display_name":"European Neuropsychopharmacology","issn_l":"0924-977X","issn":["0924-977X","1873-7862"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Neuropsychopharmacology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2192979906","https://openalex.org/W2174828092","https://openalex.org/W4206510345","https://openalex.org/W2941689848","https://openalex.org/W2050726629","https://openalex.org/W2342119439","https://openalex.org/W3005406263","https://openalex.org/W2514999534","https://openalex.org/W1980949172","https://openalex.org/W2800229081"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2016-06-24T00:00:00"}